Ulotaront hydrochloride by Sumitomo Pharma America for Generalized Anxiety Disorder (GAD): Likelihood of Approval

Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Generalized Anxiety Disorder (GAD).

Source link
#Ulotaront #hydrochloride #Sumitomo #Pharma #America #Generalized #Anxiety #Disorder #GAD #Likelihood #Approval